Rise Advisors LLC Lowers Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Rise Advisors LLC lessened its position in Kenvue Inc. (NYSE:KVUEFree Report) by 28.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,253 shares of the company’s stock after selling 505 shares during the quarter. Rise Advisors LLC’s holdings in Kenvue were worth $29,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Kenvue by 12.0% in the first quarter. Vanguard Group Inc. now owns 166,789,085 shares of the company’s stock valued at $3,579,294,000 after purchasing an additional 17,908,497 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Kenvue by 23.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company’s stock worth $2,887,773,000 after acquiring an additional 25,238,112 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Kenvue by 9.6% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 79,863,967 shares of the company’s stock valued at $1,451,927,000 after purchasing an additional 7,023,047 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Kenvue by 11.1% during the 1st quarter. JPMorgan Chase & Co. now owns 68,319,998 shares of the company’s stock worth $1,466,147,000 after purchasing an additional 6,825,611 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Kenvue by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 43,444,085 shares of the company’s stock worth $789,813,000 after purchasing an additional 7,546,362 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on KVUE shares. Deutsche Bank Aktiengesellschaft increased their price target on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. JPMorgan Chase & Co. increased their price objective on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday. UBS Group upped their price target on Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Citigroup lowered their price objective on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. Finally, Piper Sandler upped their price objective on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Kenvue has a consensus rating of “Hold” and a consensus price target of $22.20.

View Our Latest Research Report on KVUE

Kenvue Price Performance

Shares of NYSE:KVUE opened at $21.46 on Monday. The company has a market cap of $41.09 billion, a P/E ratio of 27.51, a P/E/G ratio of 2.76 and a beta of 1.40. The business has a fifty day simple moving average of $22.13 and a 200-day simple moving average of $20.18. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $23.55. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUEGet Free Report) last released its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The business had revenue of $4 billion for the quarter, compared to analysts’ expectations of $3.93 billion. During the same period last year, the company earned $0.32 earnings per share. The company’s quarterly revenue was down .3% on a year-over-year basis. Equities research analysts forecast that Kenvue Inc. will post 1.08 EPS for the current year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th were given a $0.205 dividend. This is a boost from Kenvue’s previous quarterly dividend of $0.20. This represents a $0.82 dividend on an annualized basis and a yield of 3.82%. The ex-dividend date was Wednesday, August 14th. Kenvue’s dividend payout ratio is presently 105.13%.

Kenvue Profile

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Recommended Stories

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUEFree Report).

Institutional Ownership by Quarter for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.